Immunocore Holdings plc (IMCR) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Immunocore Holdings plc (NASDAQ: IMCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $29.79 (-2.30% 1D, market cap $1.57B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMCR ranks #956 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMCR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, NVAX (Novavax Inc.) holds a D grade (49/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.66B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
Per IMCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671927), Immunocore Holdings plc generated $400.0M in revenue (+29.0% YoY), -$35.5M in net income, and -$15.1M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 1.40 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±9.2% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IMCR currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.13) and Max Pain ($31.28) forces dealer call-delta covering toward $42.76.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Immunocore Holdings plc (IMCR) dropped -2.30% to $29.79, trading at 17% of its 52-week range ($27.5 – $40.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for first combination of two
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingClinical data for first combination of two
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +29.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMCR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMCR. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Immunocore Holdings plc (IMCR) ranks #956 by composite RQD confidence (22/100, grade E) and #295 by equity capitalization ($1.57B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with IMCR at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMCR
ACTIVE
Immunocore Holdings plc | E | 22/100 | — | 96.0% | -35.0% | -2.30% | $1.57B | Benchmark Subject |
| NVAX Novavax Inc. | D | 49/100 | 3.9x | 93.5% | 85.0% | -5.46% | $1.66B | /nvax-vs-imcr → |
| REPL Replimune Group Inc. | D | 50/100 | — | — | -35.0% | +10.68% | $1.67B | /repl-vs-imcr → |
| MAZE Maze Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -3.53% | $1.75B | /maze-vs-imcr → |
| LYCA Lycia Therapeutics Inc. | D+ | 54/100 | — | — | — | +2.96% | $1.38B | /lyca-vs-imcr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immunocore Holdings plc (IMCR) reported GAAP revenue of $400.0M (+29.0% vs. FY2024 revenue of $310.2M , and +60.4% cumulative change since FY2023) , GAAP net income of -$35.5M, operating cash flow of -$10.7M, and free cash flow of -$15.1M (-172.1% YoY). On the balance sheet, IMCR closed FY2025 with $1.07B in total assets against $0 in total debt (Altman Z-Score: 1.40, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $400.0M | -$35.5M | -$10.7M | -$15.1M | $1.07B | — |
| FY2024 (FY) | 2024-12-31 | $310.2M | -$51.1M | $26.1M | $20.9M | $1.01B | — |
| FY2023 (FY) | 2023-12-31 | $249.4M | -$55.3M | $2.9M | $2.9M | — | — |
As of 2026-11-03, Immunocore Holdings plc (NASDAQ: IMCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $29.79 (-2.30% 1D, market cap $1.57B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMCR ranks #956 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMCR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, NVAX (Novavax Inc.) holds a D grade (49/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.66B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
Per IMCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671927), Immunocore Holdings plc generated $400.0M in revenue (+29.0% YoY), -$35.5M in net income, and -$15.1M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IMCR last traded at $29.79 (-2.30% on volume of 226,070 shares), positioning the stock -7.28% below its 50-day simple moving average ($32.13) and -6.14% below its 200-day simple moving average ($31.74). Across its 52-week range of $27.50 to $40.72, IMCR sits at the 17.3% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($27.05 to $32.53).
Immunocore Holdings plc (IMCR) earns a live Roarable RQD composite score of 22/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $29.79 (-2.30% 1D, market capitalization $1.57B).
Immunocore Holdings plc is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..6B. FY 2025 revenue was $400.0M against a 96% gross margin per the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Immunocore Holdings plc (IMCR) reported $400.0M in annual revenue (up from $310.2M in FY2024, +29.0% YoY) and -$35.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($249.4M revenue, -$55.3M net income) through FY2025, IMCR scaled operating cash flow to -$10.7M and free cash flow to -$15.1M, backed by $1.07B in total assets against $0 in total debt.
The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for IMCR. The second-order ripples a prospective investor would want to track, such as dependency on a single trial program or partner, are not resolved by the available data.
Real-time company headlines, analyst actions, and sector developments for Immunocore Holdings plc (IMCR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Immunocore Holdings plc (IMCR) market action, institutional positioning, and fundamental catalysts.
Don't sleep on IMCR's setup in Health Care. Revenue grew from $249.4M in FY 2023 to $400.0M in FY 2025 while operating losses narrowed, and cash stood at $467.7M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (22/100) backs up the fundamental quality.
@DeepValue_CFA Agree on the RQD 22/100 quality, though with 1.0 beta I'm scaling in with half-size at $30.49 and keeping dry powder in case we test $28.36.
I respect the product at Immunocore Holdings plc, but the stock at $30.49 is a different story. ROIC of -35%, FCF yield of -0.93%, and an Altman Z-Score of 1.4 leave the Roarable rating at 24 with a Strong Sell verdict.. FCF yield is -0.93% and RQD sits at 22/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: